Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)

Historic Accumulated Expenses for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $16.0 million.

  • Dianthus Therapeutics' Accumulated Expenses rose 10679.44% to $16.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.0 million, marking a year-over-year increase of 10679.44%. This contributed to the annual value of $13.1 million for FY2024, which is 10101.48% up from last year.
  • According to the latest figures from Q3 2025, Dianthus Therapeutics' Accumulated Expenses is $16.0 million, which was up 10679.44% from $14.0 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Accumulated Expenses peaked at $16.0 million during Q3 2025, and registered a low of $3.2 million during Q2 2023.
  • For the 4-year period, Dianthus Therapeutics' Accumulated Expenses averaged around $8.1 million, with its median value being $6.6 million (2022).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 4433.11% in 2023, then skyrocketed by 13901.31% in 2025.
  • Over the past 4 years, Dianthus Therapeutics' Accumulated Expenses (Quarter) stood at $6.6 million in 2022, then dropped by 1.57% to $6.5 million in 2023, then soared by 101.01% to $13.1 million in 2024, then rose by 22.22% to $16.0 million in 2025.
  • Its last three reported values are $16.0 million in Q3 2025, $14.0 million for Q2 2025, and $8.0 million during Q1 2025.